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Abstract
Intracellular deposition of aggregated tau is the hallmark of several
different tauopathies, the most widespread of these being Alzheimer’s disease.
Tau is a highly soluble, intrinsically disordered, microtubule associated protein.
Tau’s native function is to stabilize microtubule formation in the axons of
neurons. Post translational modification such as hyperphosphorylation as well as
several familial mutations allow tau to nucleate and form fibrils. These fibrils can
recruit healthy monomers onto their ends in a fashion described as templateassisted growth. Tau has 6 isoforms that vary by the inclusion or exclusion of two
N-terminal repeats and the inclusion or exclusion of the second of four
semiconserved repeats within its microtubule binding region. Isoforms containing
three repeats are described as 3R isoforms and those containing four repeats
are described as 4R isoforms. In Alzheimer’s disease the 3rd and 4th microtubule
binding repeats form the core of fibrils within Alzheimer’s disease. MAP2C is a
3R homologue of tau and MAP2D is 4R homologue and assists in microtubule
stabilization. The homology of MAP2 and tau within their microtubule binding
repeats gave motivation to investigate whether MAP2 could compete with tau in
binding to the ends of tau fibrils and inhibit elongation. Preliminary in-vitro data
suggest this to be the case. To further strengthen these findings, two HEK293
cell lines stably expressing two tau constructs were established; hT40P301SEYFP, a full-length tau construct C-terminally tagged with an Enhanced Yellow
ii

Fluorescence Protein, and K18P301S-EYFP, a truncated tau construct Cterminally tagged with an Enhanced Yellow Fluorescence Protein. Monoclonal
cell lines of hT40P301S-EYFP were selected and were shown to be capable of
forming intracellular puncta when transfected with K18wt seeds. Monoclonal
hT40P301S-YFP transfected cells were then used to show in culture inhibition of
fibril formation by two truncations (tr) of MAP2, MAP2Ctr and MAP2Dtr. MAP2Ctr
was able to decrease the number of cells containing puncta by 33% and
MAP2Dtr showed a 54% decrease. This data further supports the findings that
MAP2Ctr and MAP2Dtr are capable of inhibiting tau fibril elongation both in vitro
and in culture.
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1. Chapter One: Introduction

1.1

Alzheimer’s Disease

Intracellular deposition of aggregated, hyperphosphorylated tau is the
hallmark of multiple tauopathies, the most widespread of these being Alzheimer’s
Disease (AD) (1, 2). AD is pathologically characterized by the extracellular
deposition of amyloid β (Aβ) as senile plaques in combination with the
intracellular deposition of tau as neurofibrillary tangles. This aggregation leads to
symptoms such as dementia, loss of motor function, and eventually death (3). AD
is the most prevalent form of dementia and is also incurable (3). AD not only
affects individuals with the disease, but also causes a great deal of suffering for
the patient’s loved ones and those tasked with caring for the patient. AD was
responsible for the death of more than 600,000 individuals 65 and older in 2010
and is projected to take the lives of more than 1.6 million people in the year 2050
(4). The Alzheimer’s Association estimates that AD cost the United States Health
Care System $232 billion dollars in 2017; that number is expected to grow to
more than $1.1 trillion in the year 2050 with the aging of the baby boomer
population (5). There is a desperate need for further study and understanding of
tau deposition, its role within Alzheimer’s disease, and potential treatments to
prevent tau deposition.
1

1.2

Microtubule Associated Protein Tau

Microtubule Associated Protein Tau, MAPT or tau, is an unstructured,
highly soluble, protein whose primary role is to stabilize microtubules that assist
in normal neuron function, among other physiological roles (6, 7). Tau belongs to
a class of proteins described as intrinsically disordered proteins (IDP) (8–10).
These proteins are characterized by low sequence complexity, low proportions of
hydrophobic amino acids, and high proportions of charged and polar amino
acids. IDPs lack stable secondary structures and do not take on any well-defined,
globular three-dimensional structures (8). Tau stabilizes microtubule assembly by
electrostatic interactions of its microtubule binding region composed of a proline
rich region and 3 or 4 semiconserved microtubule binding repeats (MTBRs) with
microtubules in the axon of healthy neurons (6). Although tau is classified as an
IDP, it is not a random coil, and rather has a loose paperclip structure in solution
that persists for brief periods of time (11, 12). There are six distinct isoforms of
tau expressed in adult human neurons which are the result of alternate splicing of
the MAPT gene (See Figure 1.1) (13, 14). Alternate splicing of exons 2, 3, and
10, results in the inclusion or exclusion of two N-terminal inserts, and the
inclusion or exclusion of the second of four MTBRs. The longest isoform of tau is
hT40 which spans 441 amino acids and has both N-terminal inserts and all four
microtubule binding repeats (See Figure 1.1). The shortest isoform is hT23, it
spans 352 amino acids and is missing both N-terminal inserts and the second
microtubule binding repeat (15). Isoforms containing all four MTBRs are
2

described as four repeat isoforms (4R) and isoforms containing only three
MTBRs are described as three repeat isoforms (3R). 4R and 3R isoforms are
expressed at similar levels in the adult human brain (13, 16). There are two
truncations of tau commonly used in research: K18 which is a 4R isoform
spanning amino acids 244-372, and K19 which is a 3R isoform.

Figure 1.1 Tau Isoforms. 6 Isoforms of tau are expressed in the adult human
brain. These isoforms are expressed by the alternate splicing of the MAPT gene
at exons 2, 3, and 10. This results in the inclusion or exclusion of two N-terminal
inserts and the second microtubule binding repeat. Two truncations commonly
used in research are K18 and K19, which are composed of 4 or 3 microtubule
binding repeats.
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There is some evidence suggesting that post-translational modifications
such as hyperphosphorylation of tau cause it to take on conformations that allow
monomers to come together and nucleate (See Figure 1.2) (17–22). However,
post-translational modifications are not absolutely required for aggregation to
occur as recombinant, unmodified, tau is able to aggregate in vitro (23).

Figure 1.2 Depiction of Fibril Formation. Soluble tau undergoes a nucleation
event that allows it to become amyloidogenic. It is still debated whether this
nucleation event occurs with monomeric tau or whether dimers, trimers, or small
oligomers. Regardless, this event leads to the formation and propagation of
insoluble tau fibrils.

Upon nucleation, tau aggregates can recruit healthy soluble tau onto its
ends to form fibrils. In AD, these fibrils are either paired helical filaments (PHF),
or straight filaments (SF) (24, 25). The 3rd and 4th repeats of the MTBR form the
core of filaments found in AD (26). Filaments are composed of structured βsheets that stack individual strands parallel and in-register (See Figure 1.3) (27).
The aggregation of tau into filaments can be facilitated by polyanions such as
heparin, RNA, and arachidonic acid (28–31). In disease, aggregates are able to
spread to neighboring cells where they recruit soluble tau onto their ends and
create even further deposition (32–34). This method of aggregation where
4

monomers are recruited onto the ends of fibrils thereby assuming the same
conformation as the fibril is called template-assisted growth (See Figure 1.4)
(28).

Figure 1.3 Model of Tau Fibrils. A) Stacking of monomers into β-sheets
produces fibrils. B) Monomers are parrallel and in-register within the fibril. The
red arrow signifying the stacking of the same amino acids ontop of one another.

Figure 1.4 Template-Assisted Growth. Once aggregated, tau fibrils can recruit
healthy monomers onto their ends. In doing so, the recruited monomer takes on
the same conformation as the fibril it is growing onto. This method of recruitment
is described as template-assisted growth.

Template-assisted growth offers a potential target for inhibiting fibril
elongation. The ends of fibrils are responsible for the recruitment of soluble tau
5

and if the ends of the fibrils could be treated in a way that prevents monomer
from being recruited, it could halt fibril elongation in the absence of any new
breakage events (35, 36). Microtubule Associated Protein 2 (MAP2) is a
homologue of tau. MAP2 stabilizes microtubule formation in a similar fashion as
tau does. MAP2 has been shown to be expressed in human brains, primarily in
dendrites and cell bodies (37). MAP2 and tau have high sequence homology
within their MTBRs, the same sequence that forms the core of tau fibrils (See
Figure 1.5). This provided motivation to investigate whether MAP2 could
compete with tau to bind to the ends of fibrils and inhibit elongation.

Figure 1.5 Sequence Alignment of Semi-Conserved Repeats of K18, K19,
MAP2Ctr, and MAP2Dtr. Sequence alignment of the semi-conserved
microtubule binding repeats of K18, K19, MAP2Ctr, and MAP2Dtr to show
sequence homology. K18/19 are numbered with respect to hT40’s sequence
(Uniprot ID: P10636-8) and the MAP2Ctr and MAP2Dtr are numbered with
respect to MAP2D’s sequence (Uniprot ID: P15146-4). “*” denotes identical
residues, “:” denotes conserved residues, and “.” denotes semi-conserved
residues. K18wt and MAP2Dtr share 66% identical, 19% conserved, and 2%
semi-conserved, residues. K19 and MAP2Ctr share 65% identical, 16%
conserved, and 1% semi-conserved, residues. Clustal Omega was used to align
sequences.
6

1.3

Microtubule Associated Protein 2 Isoforms C and D

The MAP2 gene in humans encodes five different isoforms, MAP2A-D and
MAP2 Isoform 3 (38). MAP2C is produced by the exclusion of exons 9, 10, 11,
and 16. MAP2D is produced by the exclusion exons 9, 10, and 11, but includes
exon 16 (38). MAP2D is a 4R homologue to tau and MAP2C is a 3R homologue.
MAP2 is an IDP with little structure outside of its C-terminal domains, which
interacts with the regulatory enzyme Protein Kinase A (38). Although MAP2 has
been detected in AD brain aggregates by immunohistostaining, MAP2 has been
shown to form amorphous aggregates instead of PHF under the conditions that
would cause tau to aggregate (39). Preliminary work within our lab has shown
that MAP2 is capable of inhibiting tau aggregation in vitro. In vitro evidence
suggests that MAP2 inhibits tau elongation by competing with tau to bind onto
the ends of fibrils. This data can be found in Dr. Holden’s dissertation.

1.4

The Scope of My Research: In Culture MAP2 Inhibition

To strengthen these findings and increase the impact of future work, our
lab saw the need to develop a cellular model of tau aggregation. Previously,
other labs have used a variety of models to show intracellular tau aggregation
and the inhibition thereof. Sf9 cells, insect cells isolated from Spodoptera
frugiperda, have been used as a model for tau aggregation as tau is
phosphorylated in a similar pattern to hyperphosphorylated tau in AD NFTs (40).
N2a cells, mouse neuroblastoma cells, have been used to show inhibition of tau
7

aggregation with anthraquinones (41). Human Embryonic Kidney 293 (HEK293)
cells have previously been used as a model system to investigate inhibition of tau
aggregation with small peptide sequences (36). Our lab chose HEK293 as a
model system to show intracellular aggregation of tau and the inhibition thereof
with truncations of MAP2C and D down to residues 362-490 of MAP2D’s full
sequence here on referred to as MAP2Ctr and MAP2Dtr (See Figure 1.5). This
cell line was selected as it is an accepted model in the field. It also has increased
biological relevance as a human cell line and has been previously used to show
the inhibition of tau aggregation in culture (33–36, 42–44). The use of HEK293
cells to show in the in-culture inhibition of tau aggregation by MAP2Ctr and
MAP2Dtr follows.

8

2. Chapter Two: Methods

2.1

Tau Constructs

The longest 4R isoform of tau, hT40wt, as well as the truncated 4R tau,
K18wt, were cloned into pET-28b plasmid (See Figure 2.1). This was done using
the NcoI/Xho1 restriction sites (28). The synthesized DNA sequences were
terminated two stop codons which prevented the transcription of the His-tag.
These plasmids were then transformed into BL21 (DE3) competent cells by heat
shock method for protein expression. A hT40P301S-Enhanced Yellow
Fluorescent Protein (-EYFP) and a K18P301S-EYFP construct were cloned into
pcDNA3.1 plasmid via HindIII/Xho1 restriction sites to be used in mammalian cell
culture (See Figure 2.2). These constructs were transformed into XL1 blue cells
for DNA amplification. DNA sequences can be found in Appendix A.
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Figure 2.1 pET-28b Plasmid Map. A pET-28b plasmid map is shown above.
The XhoI and NcoI restriction sites were used to clone in genes of interest. The
synthesized DNA sequences were terminated with two stop codons to prevent
the transcription of the 6xHis tag. The lacI gene encodes for the lac operon
repressor protein that allows for induction of protein expression by IPTG. The
KanR gene provides resistance to kanamycin which allows for selection of
bacteria containing the plasmid. Plasmid map was created using SnapGene
software (from GSL Biotech; available at snapgene.com)
10

Figure 2.2 pcDNA3.1 Plasmid Map. The pcDNA3.1 Plasmid contains genes
coding for ampicillin resistance which allows for the amplification of the plasmid.
It also contains HindIII and XhoI restriction digest sites used to clone the genes
of interest into the plasmid. Resistance to Geneticin is conferred by the
NeoR/KanR gene to allow for selection of transfected cells. Plasmid map was
created using SnapGene software (from GSL Biotech; available
at snapgene.com)

2.2

MAP2 Constructs

MAP2C and D microtubule binding regions, MAP2Ctr and MAP2Dtr were
synthesized by Biomatik. These were cloned into pET-28b plasmids using
11

NcoI/Xho1 restriction sites. The synthesized DNA sequences were terminated
with two stop codons to prevent the transcription of the 6xHis tag. with Once
cloned, the plasmids were transformed into BL21 (DE3) cells for protein
expression. DNA sequences can be found in Appendix A.

2.3

Plasmid Transformation

Plasmids were transformed into either XL1 Blue Competent Cells for DNA
amplification or BL21 (DE3) Competent Cells for protein expression. Cells were
transformed by the following procedure. Competent cells and DNA were thawed
on ice for 15 min. 30 µL of cells were pipetted into a 14 ml round bottom
polypropylene tube (Corning Falcon). To this, 2 µL of pure DNA were pipetted
into the cells. This mixture incubated on ice for 30 min. Following incubation,
cells were heat shocked at 42 ºC for 50 seconds. At the completion of 50
seconds, the mixture was transferred back onto ice for 2 min. 800 µL of NZY+
media (10g/L NZ-amine, 12.5 mM MgCl2, 12.5 mM MgSO4, 20 mM glucose) was
added to the cells and incubated at 37 ºC for 45 min. 50 µL of cells were plated
onto LB Agar plates containing either 100 µg/mL of Ampicillin (pcDNA3.1 vector)
or 50 µg/mL of Kanamycin (pET-28 vector) under sterile conditions. Plates were
incubated at 37 ºC overnight until colonies grew.

12

2.4

DNA Purification

Plasmid DNA was transformed into XL1 Blue cells. A single colony was
selected from the plate and 50 mL of autoclaved Luria-Bertani Miller broth (20
g/L, Difco) and 20 µg/mL of Kanamyacin (Gold Biotechnology) in a 125 ml
Erlenmeyer flask was inoculated with the colony and incubated overnight at 37
ºC. Plasmid DNA was then purified using MIDI preparations following
manufacturer’s protocols (Qiagen) for pET-28 vectors. pcDNA3.1 vector was
purified using E.Z.N.A. Endo-Free Plasmid DNA Midi Kits following
manufacturer’s protocols (Omega Bio-Tech). DNA concentrations were quantified
using UV-Vis absorbance at 260 nm. Proteinaceous content, most importantly
endonuclease content, was assessed by the ratio of absorbance at 260 nm and
280 nm. A ratio >1.8 of 260/280 nm was used for mammalian cell culture
transfection to ensure a minimal endonuclease content.

2.5

Recombinant Protein Expression

Protocols used for protein expression are as follows. BL21 (DE3)
competent cells were previously transformed with a pET-28 vector containing the
sequence for the protein of interest. A 125 mL Erlenmeyer flask was filled with 50
mL of autoclaved Luria-Bertani Miller broth and 20 µg/mL of Kanamyacin. A
single colony was selected off the previously prepared plate that had incubated
overnight, or a prick of a previously prepared glycerol stock, and was added to
the media. This was then incubated overnight at 200 RPM and 37 ºC (12-16 h) to
13

be used as a starter culture. 15 mL of this solution was added to each culuture
flask containing 1.5 L of LB and 20 µg/mL of Kanamyacin and allowed to
incubate at 200 RPM and 37 ºC until the Optical Density (OD) at 600 nm had
reached 0.8-1.0. Each flask was then induced with 0.4 mM of IPTG (Gold
Biotechnology) and incubated for 3.5 h. The solution was then poured into 1L
Nalgene bottles and was centrifuged at 5500 x g for 10 min to pellet the cells.
Pellets were resuspended in 500 mM NaCl, 20 mM piperazine-N,N’-bis(2ethanesulfonic acid) pH 6.4 (PIPES, JT Baker), 5 mM ethylenediaminetetraacetic
acid (EDTA, Fisher), and 50 mM β-mercaptoethanol (Fisher), . Resuspended
pellets were transferred to 50 mL conical vials (Corning) and stored at -80 ºC.

2.6

Protein Purification

50 mL conical vials containing the resuspended pellets were thawed in an
80 ºC water bath for 20 min to precipitate any proteins that are not heat stable.
Tubes were then placed on ice for 5 min and sonicated using a 6 mm tip
sonicator (Fischer Scientific Model 150) at 50% power for 1 min to lyse cells and
release soluble proteins. Samples were centrifuged at 20,000 g for 30 min to
pellet any insoluble proteins and cellular debris. The remaining supernatant was
adjusted to 55% w/v (NH4)2SO4 (Ultra Pure, MP) and rocked for 1 h to precipitate
any soluble protein. Samples were centrifuged at 4,000 x g for 10 min to pellet
the precipitated protein. The supernatants were removed, and samples were
centrifuged at 4,000 x g for 10 min again to remove any remaining supernatant.
14

Pellets were taken up in 8 mL of ultrapure water (tau) or 10 mM PIPES (pH 6.4),
150 mM NaCl, 2 M Urea (MAP Proteins), each with 4 mM dithiothreitol (DTT,
Gold Biotechnology). Samples were sonicated with a 6 mm tip sonicator at 50%
power for 1 min on ice to fully resuspend the pellets. Samples were syringe
filtered through a 0.4 µm filter (Pall Acrodisk) to remove particulates. Samples
were then diluted with the previous solutions until a conductivity below 20 mS/cm
(tau) or 30 mS/cm (MAP2) was achieved. The protein sample was loaded onto a
cation exchange column (Mono S 10/100 GL, GE Healthcare) with a 50 mM
NaCl, 20 mM PIPES (pH 6.4), 0.5 mM EDTA, 2 mM DTT buffer. The protein was
eluted using a linear gradient of 1.0 M NaCl, 20 mM PIPES (pH 6.4), 0.5 mM
EDTA, and 2 mM DTT buffer. The samples were loaded onto 12%
polyacrylamide gels for full length tau, or 15% polyacrylamide for truncated tau
and truncated MAP2, and resolved by SDS-PAGE to select for fractions with the
highest purity (Appendix B). The purest fractions were pooled and adjusted to 3
mM DTT. Fractions were stored at -80 ºC until further purification by size
exclusion chromatography. The selected fractions were thawed and loaded onto
a S75 size exclusion column (GE Healthcare) for truncated tau and MAP2 or a
S200 size exclusion column (GE Healthcare) for full length tau. Both columns are
GE Healthcare XK-26/100 columns (1000 mm height, 26 mm internal diameter).
The buffer used for size exclusion was 100 mM NaCl, 20 mM 2-Amino-2(hydroxymethyl)-1,3-propanediol (pH 7.5, TRIS, Fisher), 1 mM EDTA, and 2 mM
DTT. Elution profiles can be seen in Appendix B. Collected fractions were again
15

run on an SDS-PAGE gel to select for the purest fractions (Appendix B).
Fractions were pooled and diluted in methanol (1:1 v/v) (Fisher Optima Grade)
for full length proteins or with Acetone (1:4 v/v) (Fisher Optima Grade) for
truncated proteins and adjusted to 4 mM DTT in 50 mL conical vials and
precipitated on ice at 4 ºC overnight. The precipitated protein was pelleted by
centrifugation at 12,000 x g for 10 min. Pellets were washed twice with 100%
methanol for full length protein or 100% acetone for truncated protein. Pellets
were then stored under methanol or acetone adjusted to 0.5 mM Tris(2carboxyethyl)phosphine hydrochloride (TCEP, Gold Bio) at -80 ºC.

2.7

Protein Monomerization

The supernatants were discarded from the pellets previously prepared.
Pellets were resuspended in 8M Guanidinium Hydrochloride (ThermoFisher) until
fully dissolved, 2-24 h. The protein solution was run over a PD-10 desalting
column (GE Healthcare) that had been equilibrated using assembly buffer, 100
mM NaCl, 10 mM 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid pH 7.4
(HEPES, Fisher), 0.1 mM NaN3, to exchange the protein into assembly buffer.
This was done following manufacturer’s protocols. Assembly buffer was also
used for elution. A Bicinchoninic Acid Protein Assay (BCA, Pierce) was used
following manufacturer’s protocols to determine protein concentration.

16

2.8

Fibril Formation

To form tau aggregates, the following reaction was used. Tau
concentration was adjusted to 25 µM in assembly buffer with 50 µM Heparin
(Celsus, average molecular weight 4400 KDa) and 0.5 mM TCEP at a final
volume of 500 µL. The reaction mixture was incubated at 37 ºC for 3 days for
truncated tau and 8 days for full length tau on a Barnstead Thermolyne stir plate
set to 220 RPM with a Teflon-coated micro stir bar (5x2 mm) so that the stir bar
achieved 160 RPM at this setting. To assess the quality of the formed fibrils,
reactions were ultra-centrifuged at 130,000 x g for 30 min in 1.5 mL ultracentrifuge polypropylene tubes (Beckman Coulter). The supernatants (soluble
fraction) and pellets (insoluble fractions) were separated and volumes were
adjusted using 1 X Laemmli Sample Buffer to equivolume with respect to the
original volume centrifuged. Pellets and supernatants were loaded onto 12%
polyacrylamide gels for full length proteins or 15% polyacrylamide gels for
truncated proteins and resolved by SDS-PAGE. The intensity of pellets and
supernatants were quantified using densitometry in ImageJ (45). To assess
percent growth, the following equation was used: Pellet / (Pellet + Supernatant) =
% Growth.

2.9

Seeded or Templated Reaction

To assess the ability of the formed fibrils to seed monomer, the following
reaction was performed. Fibrils formed in the previous step were sonicated at 2%
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power for 30 seconds on ice using a Fisher Sonic Dismembrator Model 100 with
a 2 mm tip to fracture the fibrils into smaller, seeding competent, fibrils. Ten µM
tau and 10% monomer equivalents of seeds (1 µM Seed), 20 µM Heparin, and
0.5 mM TCEP, were incubated at 37 ºC quiescently for 12 h. The reaction was
then ultra-centrifuged at 130,000 x g and pellets and supernatants were treated
as described in section 2.8. The amount of protein in the pellet vs. supernatant
was assessed using ImageJ densitometry measurements as described in section
2.8 (45).

2.10

HEK293 Cell Culture

HEK293 Cells were purchased from American Type Culture Collection
(ATCC). Upon arrival, the cryo-frozen sample was thawed with 1 mL of 37 ºC
Dulbecco’s Modified Eagle Medium + GlutaMAXTM-1 (DMEM, Gibco)
supplemented with 10% Fetal Bovine Serum (FBS, Gibco) and 40 U/mL of Pen
Strep (Gibco). 250 mL of DMEM and 27.5 mL of FBS was previously filtered
through a 250 mL Rapid-Flow Filter Unit 0.45 µm Polyethersulfone membrane
(Thermo) to produce 10% FBS in DMEM and to ensure sterilization. Upon
thawing, 1 mL of cells were transferred into 2, 12.5 cm2 tissue culture flasks
(CELLTREAT) containing 2 mL of 10% FBS in DMEM. Cells were grown to 70%
confluency with media changes every other day before being split into 8 chamber
cell culture slides (8 Well Polystyrene Chamber, CELLTREAT) for transfection.
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To passage cells, the media was aspirated, and cells were washed with 1
mL of Phosphate Buffered Saline (PBS pH 7.4, Gibco) to remove any dead cells
and remaining media. Enough TrypLE Express Trypsin (Gibco) was added to
cover the cells (~ 1 mL) to cleave integrins thus releasing the cells from the plate.
The cells containing TrypLE Express Trypsin were incubated at 37 ºC for 5 min
or until all cells were suspended. After that time, 1 mL of 10% FBS in DMEM was
added to the cells to halt TrypLE Express Trypsin activity. The cell suspension
was pipetted up and down against the bottom of the flask to break up any clumps
of cells. The resulting suspension was then analyzed for cell density using a
Bright Line Hemocytometer (Hausser Scientific) and plated at a density of 0.3 x
106 cells/well into 8 chamber cell culture slides for transfection.

2.11

G418 Cell Death Curve

G418 is isolated from living organisms and has several contaminating
gentamicins other than G418 (46). This leads to discrepancies between the
concentrations reported by manufacturers and the actual effective
concentrations. This requires the effective concentration to be determined for
each new lot of G418 and for each cell line it is used on. To determine the
concentration of Geneticin (G418, Gibco) to use for selection of HEK293 cells
containing the plasmid of interest, the following cell death curve was executed.
HEK293 cells that had not been transfected with pcDNA3.1 plasmid were plated
in triplicate wells of a 96-well plate (SensoPlate Plus Microplates F-Bottom,
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Greiner Bio-One) and allowed to grow to 70% confluency in 10% FBS in DMEM
with 40 U/mL of Pen Strep (Gibco). G418 was added to 10% FBS in DMEM at
concentrations ranging from 400-1000 µg/mL. The 10% FBS in DMEM with Pen
Strep media was aspirated off the cells and the 200 µL of 10% FBS in DMEM
with G418 was added (See Figure 2.3). The media was changed every 48 h to
ensure G418 concentrations were held constant and cell death was assessed
visually using a Zeiss IM 35 inverted microscope. After 7 days, cell death was
assessed and the concentration that had killed all cells within a well was used for
transfected cell growth. This concentration was found to be 700 µg/mL of G418
and was used to select for cells containing the plasmid of interest. Once selected
for, cells stably transfected with the plasmid were cultured in media containing
700 µg/mL of G418.
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Figure 2.3 Concentrations of G418 for Cell Death Curve. Cells were incubated
in DMEM containing 10% FBS and 400-1000 µg/ml of G418 in triplicate as
shown above. The media was changed every 48 h to ensure concentrations of
G418 stayed consistent. Cell death was assessed visually with an inverted
microscope daily.

2.12

Transfection of HEK293 Cells

pcDNA3.1 plasmid containing either hT40P301S-EYFP or K18P301SEYFP, purified previously in section 2.4, was transfected into HEK293 cells using
Lipofectamine 2000 Transfection Reagent (Thermo Fisher) following
manufacturer’s instructions. 24 h post transfection, the media was replaced with
10% FBS in DMEM containing 700 µg/mL of G418 to select for the cells
containing the plasmid of interest. After one week under selection media, cells
were plated onto a 96-well plate for confocal imaging to confirm stable
transfection of hT40P301S-EYFP or K18P301S-EYFP.
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2.13

Monoclonal Selection with Flow Cytometry

Following one week under selection media, cells that had been stably
transfected were split and re-plated into 100x20 mm culture plates (Nunc
Easydish 100x20 mm, Thermo Scientific) and grown to 70% confluency. Nontransfected HEK293 cells were also plated to act as a control. Cells were then
harvested using TrypLE Express Trypsin. Once cells were released from the
plate, PBS containing 1% FBS was used to halt TrypLE Express Trypsin activity
and the cells were transferred into a 15 mL conical vial. The cells were pelleted
by centrifugation at 300 x g in a swinging bucket rotor centrifuge (IEC Clinical
Centrifuge, International Equipment Company), the supernatants were removed,
and the cells were washed twice with 1% FBS in PBS. Once washing was
completed, cells were resuspended in 1 mL of 1% FBS in PBS and filtered
through a Sterile Cell Strainer (40 µm Nylon Mesh, Fisher) to remove any clumps
of cells and particulate. Cells were stored on ice until sorting. Once washed, the
cells were passed through a Sony FX500 Exchangeable Fluids Cell Sorter using
the following settings to achieve monoclonal cell lines. The Cell Sorter works by
passing cells single file through a laser that can measure the size of cells by
Forward Scattering Area (FSC-A), Back Scattering Area (BSC-A), and Forward
Scattering Width (FSC-W). It can also detect the fluorescence intensity of EYFP
within cells by using the Fluorescein Isothiocyanate Fluorescence Area channel
(FITC-A). The program’s Compensation Wizard was used to assess the control
cell’s FSC-A, BSC-A, and FITC-A to establish a “blank”. A total of 10,000 events
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were recorded. After the Compensation Wizard was completed, hT40P301SEYFP cells were loaded into the sorter. HEK293 cells stably transfected with
hT40P301S-EYFP were sorted against three gates. These gates act as a cut off
for what cells pass certain set thresholds, and which that do not. Those that pass
the first gate, Gate A, are then subjected to the thresholds of Gate B, and so on.
First, Gate A was assigned to cells sorted with a scatter plot of FSC-A vs. BSC-A
to select for cell size. Gate B sorted cells by a scatter plot of FSC-W (Forward
Scattering Width) vs. FSC-A with the gate set at a 45º angle relative to the origin.
This ensures a 1:1 ratio of area to width and therefore selects for single cells and
not cells that may be clumped together. Gate C was to set to select for cells over
a fluorescence threshold with a scatter plot of FITC-A vs. FSC-A. A 96-well plate
containing 200 µL of 10% FBS in DMEM supplemented with 40 u/mL of Pen
Strep per well was loaded into the sorter to be plated. The program was
instructed to sort a single cell that had passed gate C into each well with a 1 s
delay between wells. The plate was then incubated at 37 ºC and 5% CO2 for one
week with regular media changes until individual colonies of cells could be
confirmed by using an inverted microscope. Cells were grown to 70% confluence
before being split into 2 mL culture flasks. These were then allowed to grow to
70% confluence. Cells were then split into 96-well plates to confirm monoclonality
by confocal microscopy with excitation at 495 nm. The remaining cells were cryopreserved.
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2.14

Cryopreservation of Cell Lines

To cryogenically preserve cells for later use, the following procedure was
used. Media was aspirated off the cells and they were rinsed with 1 mL of PBS to
wash away any remaining media and remove dead cells. Enough TrypLE
Express Trypsin to cover the cells was added and the flask was incubated at 37
ºC for 5 min or until the cells were no longer adhered to the flask. 10% FBS in
DMEM was added to halt the TrypLE Express Trypsin activity and cells were
gently pipetted up and down to dissociate any clumps. The suspension was then
transferred to a 15 mL conical vial and spun at 300 x g to pellet the cells. The
supernatant was removed, and cells were resuspended in 1 mL of 10% FBS in
DMEM to rinse the cells. The cells were pelleted again and resuspended in
freezing media, (FBS supplemented with 10% v/v DMSO). The cells were then
pipetted into 1.5 mL cryogenic vials (Fisher) to be frozen. Freezing must be done
slowly as to not rupture the cells. This is accomplished by placing the cryo-tubes
into a freezer box, and then placing the freezer box in a Styrofoam container. The
container was then sealed and placed in the -80 ºC freezer for 24 hours. Once
adjusted to -80 ºC, the cells were transferred to liquid nitrogen storage.

2.15

Inhibition of Aggregation in Culture

Monoclonal hT40P301S-EYFP HEK293 cells were plated at a concentration
of 20,000-40,000 cells per well in a 96-well plate containing 10% FBS in DMEM
supplemented with 700 µg/mL of G418. Cells adhered to the plate for 24 h.
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Three-day 25 µM K18wt seeds were assessed for complete growth as described
in section 2.8. Once growth was confirmed, the seeds were tip sonicated at 20%
power for 30 seconds. Preincubation of seeds with or without MAP2 as well as a
Buffer Control (Buffer + Heparin) and MAP2 Control (Buffer + MAP2 + Heparin)
reactions were set up. Biological triplicate reactions containing 40 µM heparin
and 20 µM of K18wt seeds with or without 20 µM MAP2Ctr or MAP2Dtr in
assembly buffer were incubated at 37 ºC for 1 h. Controls containing 40 µM
heparin in assembly buffer, and 40 µM heparin with either MAP2Ctr or MAP2Dtr
were also set up and incubated. To transfect the HEK293 cells stably expressing
the gene of interest, 2 µL of lipofectamine were diluted in 5 µL of OptiMem
(Gibco) to which 10 µl of reaction mixture was added for a final seed
concentration of 1 µM per 200 µL well. The solution was vortexed and incubated
at room temp for 5 min to allow for incorporation of the proteins into the
lipofectamine liposomes. This mixture was then added to each well and pipetted
up and down gently to disperse (See Figure 2.4). Each reaction was performed
over 3 separate wells to limit pipetting errors between wells. Cells were incubated
with this mixture at 37 ºC and 5% CO2 for 6 h. After 6 h, the media was aspirated
to remove any seeds that have not been taken up by the cells and replaced with
fresh media. The cells were again incubated at 37 ºC and 5% CO2 for 6 h before
they were imaged live by confocal microscopy. Cells were assessed
quantitatively by number of cells with or without puncta. Cell were counted by
identifying their kidney bean shaped nucleus which was void of fluorescence.
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Puncta were identified as points of high fluorescent intensity within a cell, or as
small, disperse, speckled, points of intensity unique from control cells. Cells that
were lysed open were not counted. Unpaired t-test was performed using
GraphPad Prism version 8.0.0 for Windows, GraphPad Software, San Diego,
California USA, www.graphpad.com.

Figure 2.4 Experimental Set Up. K18-(1-3) denotes cells treated with each
biological replicate of K18wt seed. +C represents cells treated with seed
previously preincubated with MAP2Ctr and +D represents seed preincubated
with MAP2Dtr. +C and +D are cells treated with just MAP2Ctr or MAP2Dtr
without any K18wt seed. The cells treated with Buffer control contained neither
K18wt seed nor MAP2.

2.16

Nuclear Staining

To better quantify cells and assess the quality of cells being imaged,
Hoechst 34580 Nuclear Dye was used to stain nucleic acids within the nucleus of
the HEK293 cells. To do so, the following protocol was used. Hoechst 34580 dye
was diluted in ultrapure H2O to 10 mg/mL and was tip sonicated at 20% power to
fully dissolve to create a 10000X stock solution. Cells had been treated as
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described in section 2.15. The Hoechst 34580 10000X stock solution was diluted
to 1X in Cell Therapy Systems Dulbecco’s Phosphate Buffered Saline (DPBS
CTS, Gibco). 100 µL of the 1X dye was added directly to the 200 µL of media
within the plate. This solution was incubated at 37 ºC for 10 min, the solution was
aspirated, and replaced with 200 µL of 37 ºC 10% FBS in DMEM. The cells were
then imaged via confocal microscopy.

2.17

Confocal Imaging

Cells were imaged using an Olympus IX83 Inverted Microscope in the
EYFP channel using a UPlanFL N 40x/1.30 Oil objective (Olympus) or
UPlanSApo 60X/1.35 Oil objective (Olympus). Laser Intensity, hv, and Gain were
held constant during each individual imaging session. 3-4 images encompassing
roughly 100 cells/image were taken per well for each condition. Images were
uploaded to ImageJ and all intensities were normalized within the data set and
analyzed for total number of cells/image, and number of cells containing
puncta/image.

2.18

Triton Insoluble Pelleting and Western Blot

To further asses the inhibitory effects of MAP2Ctr and MAP2Dtr on tau
aggregation in culture, the following procedure was carried out to quantify
aggregation by triton insoluble pelleting followed by immunodetection via
Western Blot. Following imaging, cells were harvested from the 96 well plate with
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100 µL of TrypLE Express Trypsin per well. 100 µL of 1% FBS in PBS was
added to each well to halt TrypLE Express Trypsin activity and cells of the same
condition were pooled into 1.5 mL Eppendorf tubes. Cells were pelleted at 300 x
g, the supernatants were removed, and the cells were washed with PBS to
remove any remaining trypsin and re-pelleted. The supernatants were removed
and 250 µL of 1% Triton Buffer containing 25 mM Tris, pH 7.5, 150 mM NaCl, 1X
Halt Protease Inhibitor Cocktail (Thermo Fisher), and 1% v/v Trition X-100 (VWR
International), was used to resuspend the cells. The cells were incubated on ice
for 20 min and then syringe sheared through a 27 G hypodermic needle
(Covidien). To ensure equal amounts of protein were loaded onto the gel, a BCA
assay was performed on the total cell lysates to determine total protein
concentration. To pellet insoluble proteins, 100 µL of total cell lysates were ultracentrifuged at 130,000 x g for 30 min at 4 ºC. The supernatants were removed
and enough 4X Laemmli Sample Buffer was added to achieve a 1X solution and
were heated to 90 ºC. Pellets were resuspended in 1X Sample Buffer, heated to
90 ºC and tip sonicated. Samples were diluted with 1X sample buffer to match
the concentration of the sample with the lowest overall protein concentration and
were loaded onto 12% polyacrylamide gels and resolved with SDS-PAGE,
followed by electrophoretic transfer onto PVDF Western Blotting Membrane
(Sigma). All blocking, blotting, and washes were shaken on an orbital shaker
during incubation periods. The membranes were blocked with 5% w/v dry milk in
Tris-Buffered Saline with Tween-20 (TBST, 25 mM Tris, pH 7.5, 150 mM NaCl,
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0.05% Tween-20) at 4 ºC overnight. Following blocking, the membranes were
incubated for 1 h with primary antibody (GFP tag Rabbit PolyAb, #50430-2-AP
Proteintech) diluted in 5% w/v dry milk in TBST at 4 ºC. The primary antibody
solution was removed, and the membrane was washed 5x for 5 min with 5 mL of
5% w/v dry milk in TBST. After washing, the membranes were incubated with
secondary antibody (Peroxidase-conjugated Anti-Rabbit Goat, #SA00001-2
Proteintech) diluted in 5% w/v dry milk in TBST at 4 ºC for 1 h. The secondary
antibody solution was removed, and the membrane was washed 5x for 5 min
with 5 mL of 5% w/v dry milk in TBST. A final wash with 5 mL Tris-buffered saline
without Tween-20 was performed for 5 min. Following washing the,
immunoreactivity was detected using SuperSignal West Femto Maximum
Sensitivity Substrate (Thermo Scientific). Densitometry was then determined via
ImageJ to quantify the signal of the resulting bands. The amount of EYFP labeled
tau in pellets was compared.
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3. Chapter Three: Results

3.1

G418 Cell Death Curve

Our lab saw the need to establish a cell line that could act as a model
system for the in-culture aggregation of tau to further strengthen our in vitro
findings that MAP2Ctr and MAP2Dtr are capable of inhibiting tau aggregation.
The cell line HEK293 was chosen as it is a human cell line that has been
previously used to investigate the in-culture aggregation of tau and the inhibition
there of. Upon receiving the cells, they had to first be transfected with the
plasmid containing the gene of interest. Once transfected, the cells that were
stably transfected had to be selected for. The pcDNA3.2 plasmid contains a
neomycin resistance gene that allows for the selection of stably transfected cells
with G418. G418 is isolated from Micromonospora rhodorangea and the reported
concentrations vary, and some cell lines are more sensitive to the antibiotic than
others. This necessitates the establishment of a G418 cell death curve to
determine a working concentration of G418. Upon completion of the 7-day cell
death curve, it was found that 700 µg/mL of G418 in 10% FBS in DMEM was an
effective working concentration. Now that this had been established, cells could
be transfected with the gene of interest and those that were stably transfected
could be selected for.
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3.2

Transfection and Selection of Stably Transfected Cell Lines

HEK293 cells were transfected with either hT40P301S-EYFP or
K18P301S-EYFP. The P301S mutation, a familial mutation found in FTDP-17,
was used because other groups have previously shown that hT40 wild type (wt)
does not aggregate when seeded within this system (47). The -EYFP tag allows
for the detection of tau via confocal microscopy and the detection of aggregate
formation by grouping of the -EYFP into puncta. Twenty-four h after transfection
the cells were subjected to selection media containing 700 µg/mL of G418. After
7 days of incubation, cells were plated onto 96-well plates for imaging to confirm
stable transfection of the construct. In Figure 3.1 one can see the stable
transfection of both constructs within HEK293 cells.
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Figure 3.1 HEK293 Cells Stably Transfected with K18P301S-EYFP and
hT40P301S-EYFP. A & B) HEK293 cells stably transfected with K18P301SEYFP imaged in the EYFP channel. K18P301S-EYFP can be seen expressing
diffusely throughout the cell. Different cells can be seen expressing different
levels of the protein C & D) HEK293 cells stably transfected with hT40P301SEYFP imaged in the EYFP channel. The EYFP fluorescence outlines a web-like
structure that may suggest interaction of the hT40P301S-EYFP with the
microtubule network of the cell. The construct is expressing at varying levels in
different cells and is absent in the nucleus. Scale bars in A and C are 50 µm.
Scale bars in B and D are 30 µm. A and C were imaged with a 40X UPlanFL N
oil objective. B and D were imaged with a 60X UPlanSApo oil objective.
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The cells are stably expressing the EYFP-tagged tau constructs. In the
K18P301S-EYFP cells, the EYFP can be seen diffuse throughout the cell with
small amounts fluorescing within the nucleus. In contrast, within the hT40P301SEYFP cell the EYFP seems to colocalize with microtubules as web like structure
can be observed and their nucleus is devoid of fluorescence. No puncta are
observed which suggests the tau constructs are soluble and not aggregated.
These stably transfected cells, however, are expressing the EYFP tagged
constructs at varying levels between cells. This leads to complications with
imaging where some cells are too dim to be observed (low expression levels) or
too intense and saturate the camera (high expression levels) within the same
field of view. To overcome this, monoclonal selection was performed to produce
cells that express the EYFP-tagged constructs at uniform levels.

3.3

Monoclonal Cell Line Selection by Flow Cytometry

To achieve even fluorescent intensity across all cells in the plane of view,
cells that had been previously stably transfected with hT40P301S-EYFP were
sorted using a Sony FX500 Exchangeable Fluids Cell Sorter to select for a
monoclonal cell line that will express our constructs at the same level. Cells that
passed the gating described in section 2.13 were collected in a 96-well plate
containing 200 µl of DMEM with 10% FBS and 80 U/ml of Pen Strep. In all,
10,000 total cells were counted with 87.71% passing gate A, 44.11% passing
gate B, and 31.84% passing gate C (See Figure 3.2). Cells that passed gate C
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were plated at a concentration of 1 cell/well. Once these cells had grown to
confluency, they were imaged by confocal microscopy to ensure they had even
fluorescence intensity and to select a cell line for further experiments (See Figure
3.3).
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Figure 3.2 Flow Cytometry Data of hT40P301S-EYFP HEK293 Cells. Cells
were gated first by FSC-A vs BSC-A (A), then by FSC-W vs. FSC-A (B), and
finally by FSC-A vs FITC-A-Compensated (C). Cells that passed gate C were
selected and plated at a concentration of 1 cell/well. D) Shows the distribution of
cells that passed through gate B. The lower intensity cells around 102 FITC-A are
possibly in G-Phase and not expressing as much protein resulting in lower
fluorescence. Red in the heat bars of A and D represent a higher cell count
whereas black represents a lower cell count. Blue dots that are circled in B and C
represent cells that passed the gating.
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Figure 3.3 Monoclonal Cell Lines Imaged by Confocal Microscopy. A-H
show various monoclonal cell lines selected for by flow cytometry. They show
uniform fluorescence intensity and contain no puncta. Brightness was adjusted to
be uniform in all images. The cells shown in panel D were used for further
experiments. All scale bars are 50 µm. All images were viewed with a 40X
UPlanFL N oil objective.
The cells in panel D of Figure 3.3 are monoclonal and stably expressing
hT40P301S-EYFP. From here on out they are referred to as Tau Cells. All other
monoclonal cell lines were cryopreserved. Now that a monoclonal cell line has
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been established, it was necessary to show that the hT40P301S-EYFP within
Tau Cells can be recruited by transfected K18wt seeds to form intracellular
puncta.

3.4

Transfection of Cells with K18wt Seeds to Produce Intracellular
Puncta
Before cells could be transfected with K18wt seeds, it was necessary to

show that the fibrils were fully formed and that after sonication they were seeding
competent. To do so, fibrils were sedimented as described in Section 2.8, and an
overnight seeded reaction of K18wt monomer and K18wt seeds was performed
as described in section 2.9 (See Figure 3.4 and Figure 3.5). Fibrils were found to
be fully grown and could seed monomeric K18wt into fibrils. Cells were
transfected with 1 µM K18wt seeds that had been tip sonicated for 30 seconds.
After 12 h of incubation with seeds, the cells were imaged. Control cells showed
no intracellular puncta and hT40P301S-EYFP stayed diffuse throughout the cell.
Cells that had been transfected with seeds showed intracellular puncta formation
after 12 h with close to 40% of cells containing puncta. The data indicates that
the hT40P301S-EYFP within Tau Cells can form distinct intracellular puncta
when transfected with K18wt seeds (See Figure 3.6). We next sought to
determine if a decrease in the number of cells containing puncta could be
observed when seeds were preincubated with MAP2Ctr and MAP2Dtr prior to
being transfected into Tau Cells.
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Figure 3.4 K18wt Seed Formation. A) Triplicates of 3-day K18wt fibrils were
pelleted by ultra-centrifugation. Pellets (P) and supernatants (S) were loaded
onto a 15% polyacrylamide gel and resolved by SDS-PAGE and stained with
Coomassie stain. B) Densitometry measurements were made using ImageJ
software and processed using Graph Pad Prism. Percent growth was quantified
by the equation P/(P+S). The bars in B depict the mean and standard deviation
of the triplicates.

Figure 3.5 K18wt Seeded Reaction. K18wt monomer was grown onto 10%
seed:monomer 3-day K18wt seeds, quantified in Fig. 3.4, overnight. A) These
reactions were pelleted by ultra-centrifugation. Pellets (P) and supernatants (S)
were loaded onto a 15% polyacrylamide gel and resolved by SDS-PAGE and
stained with Coomassie stain. B) Densitometry measurements were made using
ImageJ software and processed using Graph Pad Prism. Percent growth was
quantified by the equation P/(P+S). The bars in B depict the mean and standard
deviation of the triplicates.
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Figure 3.6 hT40P301S-EYFP Aggregates in Tau Cells and Form Puncta
when Transfected with K18wt Seeds. A & B) Tau Cells transfected with a
buffer control and incubated for 12 h. After incubation, the hT40P301S-EYFP
stays diffuse throughout the cell with no visible puncta formation. C & D) Tau
Cells transfected with K18wt seeds and incubated for 12 h. After incubation,
distinct intracellular puncta can be observed. Scale bars in A and C are 50 µm
and the scale bars in B and D are 15 µm. The white arrows in panels C and D
denote large intercellular puncta. The red arrows denote speckled intercellular
puncta. A, B, and C were all imaged with a 40X UPlanFL N oil objective. D was
imaged with a 60X UPlanSApo oil objective.
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3.5

Inhibition of Aggregation in Culture with MAP2Ctr and MAP2Dtr
Tau Cells have been shown to form intracellular puncta when transfected

with K18wt seeds. We now sought to determine whether puncta formation could
be inhibited by pretreating the K18wt seeds with MAP2Ctr or MAP2Dtr. MAP2Ctr
and MAP2Dtr can be seen resolved by SDS-PAGE and stained with Coomassie
stain in Figure 3.7. Tau Cells were transfected with either 1 µM K18wt seeds, 1
µM K18wt seeds preincubated with 1 µM MAP2Ctr, or 1 µM K18wt seeds
preincubated with 1 µM MAP2Dtr. This was done with three separate sets of
K18wt seeds to form biological triplicates. Tau Cells were also transfected with
buffer alone, MAP2Ctr alone, and MAP2Dtr alone, to act as controls to show that
MAP2Ctr and MAP2Dtr do not form puncta. After 6 h of incubation with seeds,
the media was changed to remove any seeds that had not been taken up by the
cells and cells were incubated for an additional 6 h. After this time, cells were
imaged and the number of cells containing puncta vs the total number of cells
were quantified. Images were collected from three separate wells of each
condition. Over 1000 cells per condition were counted. A significant decrease in
the number of cells containing puncta was observed when K18wt seeds were
preincubation with MAP2Ctr and MAP2Dtr compared to cells that received K18wt
seeds that had not been preincubated with MAP2. Cells given K18wt seeds saw
38.5 +/- 1.2% of cells containing puncta, alternatively, cells given seeds
preincubated with MAP2Ctr saw only 26.8 +/- 0.2% of cells containing puncta
and only 18.3 +/- 3.0% for seeds preincubated with MAP2Dtr. When normalized
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so that the number of cells containing puncta when transfected with K18wt seeds
alone is equal to 100%, this represents a 32.9% decrease in cells with puncta for
MAP2Ctr and a 54.3% decrease in cells with puncta for MAP2Dtr (See Figure 3.8
and Figure 3.9). Tau Cells given buffer alone with no seed, MAP2Ctr, or
MAP2Dtr, showed no puncta formation (See Appendix C). Collectively, the data
revealed that MAP2Ctr and MAP2Dtr are capable of inhibiting tau fibril elongation
in culture. Total cell count was determined by counting the dark spaces where
the nucleus is. To reassure ourselves that the cell count was accurate, we sought
to use a nuclear dye that would assist in differentiating individual cells from one
another.

Figure 3.7 MAP2Ctr and MAP2Dtr Protein. 10 µM MAP2Ctr and MAP2Dtr
loaded onto a 15% polyacrylamide gel and resolved by SDS-PAGE to show
protein purity.
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Figure 3.8 Inhibition of Aggregation by MAP2Ctr and Dtr. A) Tau Cells
transfected with a buffer control. Tau is diffuse throughout the cell and void from
the nucleus. B) Tau Cells transfected with K18wt seeds. Aggregated
hT40P301S-EYFP are observable as distinct puncta, 38.5% of cells contain
puncta. C) A 33% normalized reduction in cells containing puncta was observed
in Tau Cells that were given K18wt preincubated with MAP2Ctr. D) A 54%
normalized reduction in Tau Cells containing puncta was observed when K18wt
seeds were preincubated with MAP2Dtr. All scale bars are 50 µm. Brightness
was adjusted to be consistent in all images. All images were viewed with a 40X
UPlanFL N oil objective
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Figure 3.9 Inhibition of hT40P301S-EYFP Aggregation with MAP2Ctr and
Dtr. Tau Cells were separately transfected with biological triplicates of K18wt
seed that had either been untreated or preincubated with either MAP2Ctr or
MAP2Dtr. Percent total cells containing puncta were quantified after 12 h of
incubation with these seeds. Data was normalized to K18wt without MAP2
preincubation. The bars represent the mean of biological triplicates with error
bars representing SD. Statistical significance was assessed by unpaired t-test via
Graph Pad Prism. ***=p ≤ 0.001. This decrease in the number of cells containing
puncta when K18wt is preincubated with either MAP2Ctr or MAP2Dtr suggests
that MAP2Ctr and MAP2Dtr are capable of inhibiting K18wt’s ability to recruit
soluble tau in culture.
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3.6

Hoechst 34580 Staining

Previously, total cell count was assessed visually by counting the nuclei
which were assumed to be the dark spots devoid of EYFP fluorescence in the
center of cells. However, some cells under stressed conditions had nuclei that
had divided, thus making counting difficult. Without a stain the nuclei could not be
confirmed. To improve upon this method of counting, Hoechst 34580 nuclear
stain was applied to the cells. Hoechst 34580 was chosen because it is cellpermeant and can be used to image live cells without the need to fix or permeate
the membrane. Hoechst fluoresces upon binding to double stranded DNA and
has a very small background signal. Preliminary data of the nuclear staining can
be seen in Figure 3.10. Unfortunately, current staining protocols result in a
significant number of cells being washed away and the appearance of the cells
changes following treatment. Cells have been observed rounding up and their
fluorescence intensity increases after treatment. Changes to the protocol will
continue to be assessed. To further support the confocal findings, triton insoluble
pelleting of in culture aggregates was used.
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Figure 3.10 Tau Cells Stained with Hoechst 34580. A & B) Tau Cells stained
with Hoechst 34580. Magenta represents the Hoechst dye fluorescing in the
DAPI channel, and green is the EYFP signal imaged in the EYFP channel. Cells
in A are of a higher quality with little variance in signal intensity. Cells in B are
rounded, and their intensity varies. Cells indicated by the red arrows are cells
with abnormal nuclei that suggest the cells are in poor health. These cells would
be excluded from counting.

3.7

Biochemical Analysis of Protein Aggregates

To support the inhibitory findings produced by confocal microscopy, a
biochemical assay of the tau aggregates was performed. Tau aggregates from
cells are insoluble in mild detergents such as 1% Triton X-100 or 1% Sarkosyl
solutions (47). This allows for the separation of tau aggregates from soluble
monomer by sedimentation of cell lysates. Once sedimented, the pellets can be
loaded on a 12% polyacrylamide gel, resolved by SDS-PAGE, and biochemically
analyzed by Western Blot to quantify the amount of tau in pellets. In theory, one
would expect to see a decrease in tau present in the pellets of cells that were
given K18wt seeds preincubated with MAP2 vs cells that were given untreated
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K18wt seeds. However, there have been complications with the pelleting
procedure and only preliminary data using the supernatants has been produced
(See Figure 3.11). This data confirms the antibodies function as desired and
EYFP tagged tau can be detected. Further development of the triton insoluble
pelleting procedure will be performed.

Figure 3.11 Western Blot of Supernatants of Tau Cells. Tau Cells were
transfected with either a buffer control (Buff), K18wt seeds in triplicates, K18wt
seeds preincubated with either MAP2Ctr or MAP2Dtr, MAP2Ctr alone, or
MAP2Dtr alone. Cells were lysed in 1% Triton buffer and pelleted at 130,000 x g.
Supernatants were resolved by SDS-PAGE, transferred onto blotting material,
and blotted with rabbit anti-GFP Ab. A secondary goat anti-rabbit Ab conjugated
to horse radish peroxidase was used for detection by chemiluminescence.
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4. Chapter Four: Discussion

4.1

Established HEK293 Cell Lines Stably Expressing hT40P301S-EYFP
and K18P301S-EYFP
The first goal of this project was to establish HEK293 cell lines that were

stably transfected with and expressing hT40P301S-EYFP or K18P301S-EYFP.
This was accomplished through lipofectamine transfection of pcDNA3.1 plasmid
containing the genes of interest. After 1 week under selection media, the cells
were imaged by confocal microscopy to confirm expression of the EYFP tagged
K18P301S and hT40P301S. It was noted that K18P301S-EYFP cells had
characteristics distinct from that of hT40P301S-EYFP. While K18P301S-EYFP
was defuse within the cell, and even showed low fluorescence within the nucleus,
it did not appear to localize to the microtubules. Interestingly, hT40P301S-EYFP
appeared to interact strongly with microtubules allowing for the appearance of
web-like structures within the cells. This suggest that the hT40P301S-EYFP
could be performing its native function of stabilizing microtubules. This cannot be
confirmed simply by this observation and further experiments, such as staining
for microtubules and measuring colocalization, would further strengthen this
hypothesis. The interaction of GFP tagged hT40wt with microtubules has been
seen previously in PC12 cells (48). Although K18P301S-EYFP did not appear to
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be interacting as strongly with microtubules as hT40P301S-EYFP, this
does not mean it is not performing its native function. K18wt has a Kd of 25.5 µM
for microtubule binding which is much higher than hT40wt’s Kd of 1.1 µM (49).
This means K18 has a much lower binding affinity for microtubules than hT40
does. It is possible that K18P301S-EYFP is in fact interacting with microtubules,
but its on-off rate is too rapid for it to outline the microtubules as hT40P301SEYFP does.
Although these cells are stably transfected and expressing the plasmid of
interest, they were expressing the EYFP at varying levels. This difference is
caused by various cells integrating a different number of plasmids into their
genome, resulting in varying fluorescence intensity from cell to cell. Not only
were the cells fluorescing at different intensities, but some were not fluorescing at
all. It is possible that some cells have cleaved the plasmid within the gene of
interest before integration. These cells can still express the resistance gene and
thus survive the selection media, but do not express the gene of interest.
Because of this, the cells were subjected to monoclonal selection to ensure the
cells were fluorescing and that the intensity of fluorescence was consistent from
cell to cell. Once the Tau Cells were selected, they were transfected with K18wt
seeds to ensure that the hT40P301S-EYFP could be recruited onto the seeds
and form intracellular puncta that could be viewed by confocal microscopy.
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4.2

Stably Transfected Cells Produce Puncta when Transfected with
K18wt Seeds
When hT40P301S-EYFP expressing cells were transfected with K18wt

seeds, the web-like structures were often disrupted suggesting hT40P301SEYFP was no longer interacting with the microtubule network. The EYFP
fluorescence would cluster into distinct, bright, puncta of high intensity relative to
the rest of the cell when seeds were present. These puncta were not observed in
the absence of seeds when the cells were transfected with a buffer control,
MAP2Ctr alone, or MAP2Dtr alone. The formation of puncta suggests that the
hT40P301S-EYFP is no longer soluble but is instead being recruited onto the
ends of the K18wt seeds and forming fibrils, resulting in a clustering of EYFP
seen as bright puncta when viewed under confocal microscopy. It has previously
been observed that hT40P301S is capable of being recruited by K18wt seeds in
culture, and this holds true for our EYFP tagged construct (50). K18P301S-EYFP
cells were both capable of forming puncta when transfected with K18wt seeds
(See Appendix C). K18P301S-EYFP cells showed unique puncta morphology
when the cells were transfected with K18wt seeds from those formed by
hT40P301S-EYFP. While K18P301S-EYFP formed relatively large and often
singular puncta within cells, hT40P301S-EYFP was observed to form many
more, smaller, diffuse puncta within cells as well as larger puncta. When viewed
under confocal microscopy, these smaller puncta formed by hT40P301S-EYFP
could be seen being shuttled around the cell whereas the larger hT40P301S49

EYFP were stationary. This shuttling of small aggregates was not observed for
K18P301S-EYFP. Similar diversity in puncta morphology has been observed
previously in other tau models (51). The difference in puncta morphology could
be due to the presence of the N- and C-termini in the hT40P301S-EYFP
construct. It would be interesting to see how the morphology of puncta may differ
for other seed types that have been shown to have different conformations than
K18wt. For example, how do these puncta look and behave for seeds composed
of hT40wt monomer? hT40wt fibrils show more order in the 4R than K18wt fibrils
do and this change in conformation could result in unique puncta morphology
(52). Now that it has been shown that K18wt seeds can recruit hT40P301S-YFP
to form intracellular puncta in HEK293 cells, we wanted to see if puncta formation
could be inhibited by MAP2Ctr and MAP2Dtr.

4.3

Inhibition of Intracellular Puncta Formation by MAP2Ctr and
MAP2Dtr

Tau Cells were transfected with seeds that were either preincubated with
MAP2Ctr, MAP2Dtr, or just buffer. The cells that received seeds that had been
preincubated with MAP2 showed a significant reduction in cells containing puncta
with MAP2Dtr being able to decrease cells containing puncta by 54.3%. This
suggest a potential mechanism of inhibiting tau fibril elongation by out-competing
hT40P301S-EYFP recruitment. Further investigation into the precise sequence of
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MAP2 responsible for this inhibitory mechanism is needed as it could produce a
smaller peptide that would inhibit tau fibril elongation.
Cells that were treated with K18wt seeds, either treated or not, had an
overall higher fluorescent intensity than the control cells. This could be due to the
pcDNA3.1 plasmid used for transfection of the hT40P301S-EYFP construct. The
pcDNA3.1 plasmid contains a cytomegalovirus (CMV) enhance-promoter for high
expression levels of the gene of interest. This promoter is enhanced by
transcription factors such as cAMP response element-binding protein, activator
protein 1, and specific protein 1, all of which are involved in stress response
within the cell (53). This could lead to increased expression levels of
hT40P301S-YFP as a response to the toxic aggregates (54).
It was also noted that the ability for MAP2 to inhibit puncta formation in
culture was lost over time (data not shown). The K18wt seeds were preincubated
with MAP2Ctr and MAP2Dtr before being transfected into the cells. Due to this
method of treating the seeds, the supply of MAP2Ctr and MAP2Dtr is cut off
post-transfection. To the contrary there is a constant supply of hT40P301S-EYFP
within the cells. The resulting effect is that any K18wt seed that was not capped,
or the MAP2 dissociated from its end, has the propensity to elongate, fracture,
and spread, not only intracellularly but potentially intercellularly as well (34).
MAP2 could be removed from the fibrils by proteolytic means, or fibrils could be
fractured potentially by chaperones, exposing new ends that could recruit tau
(55, 56).
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4.4

Further Investigation into in-culture Inhibition Effects of MAP2Ctr
and MAP2Dtr
To improve upon the confocal findings, Hoechst 34580 dye was used to

stain the nuclei of cells and assist in more consistent and accurate cell counting.
Currently, the dye is added directly to the media after the full 12h incubation. The
dye is incubated cells for 10 min at 37 ºC so the dye can permeate the cells. The
media is changed following the 10 min incubation to remove any excess dye.
This protocol has greatly improved the quality of images and the over health of
the cells. Previous methods had led to the cells being washed away or damaged
in the process. However, even with the improvements made to the protocol, the
images are still not of a quality comparable to those that had not been dyed. One
way to improve upon this problem could be to coat the plate with poly-D-lysine.
This could adhere the cells more strongly to the plate and prevent them from
being washed away (54). Another possible solution could be to lower the dye
concentration and allow for a longer recovery period after staining.
We also sought to show the reduction of tau aggregation in culture
through a biochemical assay. Tau aggregates are insoluble in 1% Triton X-100 or
sarkosyl solutions and several labs have exploited this to separate aggregates
from monomeric tau in culture (47, 57–59). I sought to use this method to isolate
aggregates from cells to show a reduction in EYFP labeled tau in the pellets
when the cells were transfected with treated seeds. However, the protocol needs
further improvements. Currently, a 1% Triton X-100 solution is being used, but a
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1% sarkosyl solution could be used instead if the triton solution continues to be
unsuccessful.

4.5

Summary

The goal of this project was to establish a human cell line that could test in
culture inhibition of tau aggregation by MAP2Ctr and MAP2Dtr. HEK293 cell lines
stably expressing K18P301S-EYFP or hT40P301S-EYFP were successfully
established and a monoclonal cell line expressing hT40P301S-EYFP was
selected. The hT40P301S-EYFP cell line was used to show that when
transfected with K18wt seeds, the seeds could successfully recruit hT40P301SEYFP to form intracellular puncta. The hT40P301S-EYFP cell line was then used
to show in culture inhibition of tau aggregation by MAP2Ctr and MAP2Dtr. This
cell line is a powerful model that can be used for future research within the lab.
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6. Appendix A: Construct Sequences
MAP2Ctr DNA Sequence:
CGCCTGATTAATCAGCCTTTACCGGATCTGAAAAATGTTAAATCTAAAATCG
GCTCTACGGATAATATCAAATATCAGCCTAAAGGTGGTCAGGTTCAGATTGT
GACCAAAAAGATCGATCTGTCACATGTGACGAGTAAATGCGGTTCACTGAAA
AATATCCGTCATAGGCCAGGTGGCGGTCGTGTTAAAATCGAATCTGTTAAAC
TGGATTTTAAAGAAAAAGCGCAGGCCAAAGTGGGTTCTTTAGATAATGCCCA
TCATGTTCCGGGTGGCGGTAATGTTAAA
MAP2Dtr DNA Sequence:
CGTCTGATTAATCAGCCTCTGCCGGATCTGAAAAATGTTAAATCTAAAATTG
GCTCAACCGATAATATCAAATATCAGCCTAAAGGCGGTCAGGTTCGCATCCT
GAACAAGAAGATCGATTTTAGCAAAGTGCAGTCACGTTGCGGCAGTAAAGA
TAATATCAAACATAGCGCCGGCGGAGGTAATGTGCAGATTGTGACCAAGAA
GATCGATCTGTCACATGTGACAAGTAAATGCGGTTCACTGAAAAATATTCGT
CATCGTCCGGGTGGCGGTCGTGTTAAAATCGAATCAGTTAAACTGGATTTTA
AAGAAAAAGCCCAGGCCAAAGTGGGCTCACTGGATAATGCACATCATGTTC
CAGGTGGTGGCAATGTTAAAATTGAT
hT40P301S-EYFP DNA Sequence:
AAGCTTACCATGGCTGAGCCCCGCCAGGAGTTCGAAGTGATGGAAGATCAC
GCTGGGACGTACGGGTTGGGGGACAGGAAAGATCAGGGGGGCTACACCAT
GCACCAAGACCAAGAGGGTGACACGGACGCTGGCCTGAAAGAATCTCCCC
TGCAGACCCCCACTGAGGACGGATCTGAGGAACCGGGCTCTGAAACCTCT
GATGCTAAGAGCACTCCAACAGCGGAAGATGTGACAGCACCCTTAGTGGAT
GAGGGAGCTCCCGGCAAGCAGGCTGCCGCGCAGCCCCACACGGAGATCC
CAGAAGGAACCACAGCTGAAGAAGCAGGCATTGGAGACACCCCCAGCCTG
GAAGACGAAGCTGCTGGTCACGTGACCCAAGCTCGCATGGTCAGTAAAAGC
AAAGACGGGACTGGAAGCGATGACAAAAAAGCCAAGGGGGCTGATGGTAA
AACGAAGATCGCCACACCGCGGGGAGCAGCCCCTCCAGGCCAGAAGGGC
CAGGCCAACGCCACCAGGATTCCAGCAAAAACCCCGCCCGCTCCAAAGAC
ACCACCCAGCTCTGGTGAACCTCCAAAATCAGGGGATCGCAGCGGCTACA
GCAGCCCCGGCTCCCCAGGCACTCCCGGCAGCCGCTCCCGCACCCCGTC
CCTTCCAACCCCACCCACCCGGGAGCCCAAGAAGGTGGCAGTGGTCCGTA
CTCCACCCAAGTCGCCGTCTTCCGCCAAGAGCCGCCTGCAGACAGCCCCC
GTGCCCATGCCAGACCTGAAGAATGTCAAGTCCAAGATCGGCTCCACTGAG
AACCTGAAGCACCAGCCGGGAGGCGGGAAGGTGCAGATAATTAATAAGAA
GCTGGATCTTAGCAACGTCCAGTCCAAGTGTGGCTCAAAGGATAATATCAAA
CACGTCAGCGGAGGCGGCAGTGTGCAAATAGTCTACAAACCAGTTGACCTG
AGCAAGGTGACCTCCAAGTGTGGCTCATTAGGCAACATCCATCATAAACCA
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GGAGGTGGCCAGGTGGAAGTAAAATCTGAGAAGCTGGACTTCAAGGACAG
AGTCCAGTCGAAGATTGGGTCCCTGGACAATATCACCCACGTCCCTGGCGG
AGGAAATAAAAAGATTGAAACCCACAAGCTGACCTTCCGCGAGAACGCCAA
AGCCAAGACAGACCACGGGGCGGAGATCGTGTACAAGTCGCCAGTGGTGT
CTGGGGACACGTCTCCACGGCATCTCAGCAATGTCTCCTCCACCGGCAGCA
TCGACATGGTAGACTCGCCCCAGCTCGCCACGCTAGCTGACGAGGTGTCT
GCCTCCCTGGCCAAGCAGGGTTTGGGCGGAGGCGGGAGCGGCGGAGGCG
GAAGCGGCGGCGGAGGCAGCGGCGGCGGAGGATCCATGGTGAGCAAGGG
CGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCG
ACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCC
ACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCC
GTGCCCTGGCCCACCCTCGTGACCACCTTCGGCTACGGCCTGCAGTGCTT
CGCCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCAT
GCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCA
ACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAAC
CGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGG
GCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGA
CAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGA
GGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCG
GCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCTACCAGTCC
GCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGA
GTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGT
AATGATAACTCGAG

hT40P301S-EYFP Amino Acid Sequence:
MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQTP
TEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEGTTAE
EAGIGDTPSLEDEAAGHVTQARMVSKSKDGTGSDDKKAKGADGKTKIATPRGA
APPGQKGQANATRIPAKTPPAPKTPPSSGEPPKSGDRSGYSSPGSPGTPGSR
SRTPSLPTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGST
ENLKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVSGGGSVQIVYKPVDLSK
VTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKI
ETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTGSIDMVDSPQL
ATLADEVSASLAKQGLGGGGSGGGGSGGGGSGGGGSMVSKGEELFTGVVPI
LVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTFGYGL
QCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLV
NRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSV
QLADHYQQNTPIGDGPVLLPDNHYLSYQSALSKDPNEKRDHMVLLEFVTAAGIT
LGMDELYK
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Red denotes the amino acid sequence of K18P301S, the blue denotes the linker
sequences used to link K18P301S to YFP, and the yellow is the amino acid
sequence for YFP.

K18P301S-EYFP DNA Sequnce:
AAGCTTACCATGGGCCAGACAGCCCCCGTGCCCATGCCAGACCTGAAGAAT
GTCAAGTCCAAGATCGGCTCCACTGAGAACCTGAAGCACCAGCCGGGAGG
CGGGAAGGTGCAGATAATTAATAAGAAGCTGGATCTTAGCAACGTCCAGTC
CAAGTGTGGCTCAAAGGATAATATCAAACACGTCAGCGGAGGCGGCAGTGT
GCAAATAGTCTACAAACCAGTTGACCTGAGCAAGGTGACCTCCAAGTGTGG
CTCATTAGGCAACATCCATCATAAACCAGGAGGTGGCCAGGTGGAAGTAAA
ATCTGAGAAGCTGGACTTCAAGGACAGAGTCCAGTCGAAGATTGGGTCCCT
GGACAATATCACCCACGTCCCTGGCGGAGGAAATAAAAAGATTGAAGGCGG
AGGCGGGAGCGGCGGAGGCGGAAGCGGCGGCGGAGGCAGCGGCGGCGG
AGGATCCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCA
TCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCC
GGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCAT
CTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCT
TCGGCTACGGCCTGCAGTGCTTCGCCCGCTACCCCGACCACATGAAGCAG
CACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCAC
CATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTT
CGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCA
AGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGC
CACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAAC
TTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCA
CTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACA
ACCACTACCTGAGCTACCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGC
GCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTC
GGCATGGACGAGCTGTACAAGTAATGATAACTCGAG
K18P301S-EYFP Amino Acid Sequence:
MGQTAPVPMPDLKNVKSKIGSTENLKHQPGGGKVQIINKKLDLSNVQSKCGSK
DNIKHVSGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFK
DRVQSKIGSLDNITHVPGGGNKKIEGGGGSGGGGSGGGGSGGGGSMVSKGE
ELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPT
LVTTFGYGLQCFARYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEV
KFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKI
RHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSYQSALSKDPNEKRDHMVL
LEFVTAAGITLGMDELYK
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Red denotes the amino acid sequence of K18P301S, the blue denotes the linker
sequences used to link K18P301S to YFP, and the yellow is the amino acid
sequence for YFP.
hT40wt DNA Sequence:
ATGGCTGAGCCCCGCCAGGAGTTCGAAGTGATGGAAGATCACGCTGGGAC
GTACGGGTTGGGGGACAGGAAAGATCAGGGGGGCTACACCATGCACCAAG
ACCAAGAGGGTGACACGGACGCTGGCCTGAAAGAATCTCCCCTGCAGACC
CCCACTGAGGACGGATCTGAGGAACCGGGCTCTGAAACCTCTGATGCTAAG
AGCACTCCAACAGCGGAAGATGTGACAGCACCCTTAGTGGATGAGGGAGC
TCCCGGCAAGCAGGCTGCCGCGCAGCCCCACACGGAGATCCCAGAAGGAA
CCACAGCTGAAGAAGCAGGCATTGGAGACACCCCCAGCCTGGAAGACGAA
GCTGCTGGTCACGTGACCCAAGCTCGCATGGTCAGTAAAAGCAAAGACGG
GACTGGAAGCGATGACAAAAAAGCCAAGGGGGCTGATGGTAAAACGAAGAT
CGCCACACCGCGGGGAGCAGCCCCTCCAGGCCAGAAGGGCCAGGCCAAC
GCCACCAGGATTCCAGCAAAAACCCCGCCCGCTCCAAAGACACCACCCAG
CTCTGGTGAACCTCCAAAATCAGGGGATCGCAGCGGCTACAGCAGCCCCG
GCTCCCCAGGCACTCCCGGCAGCCGCTCCCGCACCCCGTCCCTTCCAACC
CCACCCACCCGGGAGCCCAAGAAGGTGGCAGTGGTCCGTACTCCACCCAA
GTCGCCGTCTTCCGCCAAGAGCCGCCTGCAGACAGCCCCCGTGCCCATGC
CAGACCTGAAGAATGTCAAGTCCAAGATCGGCTCCACTGAGAACCTGAAGC
ACCAGCCGGGAGGCGGGAAGGTGCAGATAATTAATAAGAAGCTGGATCTTA
GCAACGTCCAGTCCAAGAGCGGCTCAAAGGATAATATCAAACACGTCCCGG
GAGGCGGCAGTGTGCAAATAGTCTACAAACCAGTTGACCTGAGCAAGGTGA
CCTCCAAGAGCGGCTCATTAGGCAACATCCATCATAAACCAGGAGGTGGCC
AGGTGGAAGTAAAATCTGAGAAGCTTGACTTCAAGGACAGAGTCCAGTCGA
AGATTGGGTCCCTGGACAATATCACCCACGTCCCTGGCGGAGGAAATAAAA
AGATTGAAACCCACAAGCTGACCTTCCGCGAGAACGCCAAAGCCAAGACAG
ACCACGGGGCGGAGATCGTGTACAAGTCGCCAGTGGTGTCTGGGGACACG
TCTCCACGGCATCTCAGCAATGTCTCCTCCACCGGCAGCATCGACATGGTA
GACTCGCCCCAGCTCGCCACGCTAGCTGACGAGGTGTCTGCCTCCCTGGC
CAAGCAGGGTTTG
K18wt DNA Sequence:
ATGGGCCAGACAGCCCCCGTGCCCATGCCAGACCTGAAGAATGTCAAGTC
CAAGATCGGCTCCACTGAGAACCTGAAGCACCAGCCGGGAGGCGGGAAGG
TGCAGATAATTAATAAGAAGCTGGATCTTAGCAACGTCCAGTCCAAGTGTGG
CTCAAAGGATAATATCAAACACGTCAGCGGAGGCGGCAGTGTGCAAATAGT
CTACAAACCAGTTGACCTGAGCAAGGTGACCTCCAAGTGTGGCTCATTAGG
CAACATCCATCATAAACCAGGAGGTGGCCAGGTGGAAGTAAAATCTGAGAA
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GCTGGACTTCAAGGACAGAGTCCAGTCGAAGATTGGGTCCCTGGACAATAT
CACCCACGTCCCTGGCGGAGGAAATAAAAAGATTGAA
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7. Appendix B: Protein Purification
K18wt Ion Exchange Elution Profile:

Elution profile of K18wt off the ion exchange column. The blue line denotes the
UV abs at 280 nm. The brown line is the conductivity as the 1 M NaCl gradient is
applied.
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Fractions 9-15 of the trace above loaded onto a 15% polyacrylamide gel and
resolved by SDS-PAGE to asses purity. Fractions 13-15 were pooled for size
exclusion
K18wt Size Exclusion Elution Profile:

Elution profile of K18wt off the size exclusion column. The blue trace is the UV
abs at 280 nm.
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Fractions 47-58 were loaded onto a 15% polyacrylamide gel and resolved by
SDS-PAGE to asses protein purity. Fractions 52-56 were pooled and precipitated
to be monomerized.

8. Appendix C: MAP2 Inhibition Controls and K18P301S-YFP Puncta

Tau Cells treated with 1 µM MAP2Ctr (A) or MAP2Dtr (B). Neither conditions
show intracellular puncta formation.
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K18P301S-YFP cells transfected with 1 µM K18wt seeds. They form larger, more
discrete puncta than the hT40P301S-YFP puncta.
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